New medicine for rare, chronic liver disease
Ocaliva recommended for conditional approval
The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) to Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis (also known as primary biliary cirrhosis). Ocaliva is to be used in combination with another medicine, ursodeoxycholic acid (UDCA), in patients who have not responded adequately to UDCA, or on its own in adults who are unable to tolerate treatment with UDCA.
Primary biliary cholangitis is a rare and life-threatening disease that causes the gradual destruction of the small bile ducts in the liver. These ducts transport fluid called bile from the liver towards the intestines where it is used to help digest fats. As a result of the destruction of the ducts, bile builds up in the liver causing damage. As the disease progresses, it leads to liver cirrhosis (scarring of the liver) and liver failure, and may increase the risk of liver cancer.
There are limited treatments available for patients with primary biliary cholangitis. Liver transplantation can significantly improve a patient’s chance of survival; however this is a long and complex operation only suitable for patients who have advanced liver disease. UDCA is the only medicine currently approved to treat primary biliary cholangitis, but up to half of all patients treated with UDCA either fail to respond to the medicine or experience limited benefits. There is therefore a clear unmet medical need for these patients, as well as for patients who are unable to tolerate treatment with UDCA.
Obeticholic acid is a semi-synthetic bile acid that works by activating the farnesoid X receptor (FXR), which controls the production of bile. By activating this receptor, Ocaliva is expected to reduce the production of bile in the liver, thus reducing the exposure of the liver to toxic levels of bile acids.
EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a conditional marketing authorisation for Ocaliva. Conditional approval is one of EMA’s main mechanisms to facilitate earlier access by patients to medicines that fulfil unmet medical needs. It allows the Agency to recommend a medicine for marketing authorisation before the availability of confirmatory clinical trial data, if the benefits of making this medicine available to patients immediately outweigh the risks inherent in the lack of comprehensive data.
The safety and efficacy of Ocaliva were demonstrated in a phase III study with 216 participants. After 12 months, the proportion of patients achieving reductions in levels of their alkaline phosphatase (an indicator of disease progression) was higher in patients treated with Ocaliva (about 47% compared to 10% in the placebo group).
The most common side effects observed with Ocaliva were itching of the skin (pruritus) and fatigue.
As part of the conditional marketing authorisation, the applicant for Ocaliva has to provide results from two studies. Until availability of full data, the CHMP will review the benefits and risks of Ocaliva annually to determine whether the conditional marketing authorisation can be maintained.
Because primary biliary cholangitis is rare, Ocaliva received an orphan designation from EMA’s Committee for Orphan Medicinal Products (COMP) in 2010. Orphan designation is the key instrument available in the EU to encourage the development of medicines for patients with rare diseases. Orphan-designated medicines qualify for ten years’ market exclusivity. In addition orphan designation gives medicine developers access to incentives, such as fee reductions for marketing authorisation applications and forscientific advice.
The applicant received scientific advice from the CHMP on the quality, preclinical and clinical aspects of the dossier.
The opinion adopted by the CHMP at its October 2016 meeting is an intermediary step on Ocaliva’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once a marketing authorisation has been granted, a decision on price and reimbursement will then take place at the level of each Member State considering the potential role/use of the medicine in the context of the national health system of that country.
- The applicant for Ocaliva is Intercept Pharma Ltd.
- Following this positive CHMP opinion, the COMP will assess whether the orphan designation should be maintained.
|Name||Language||First published||Last updated|
|New medicine for rare, chronic liver disease||(English only)||14/10/2016|
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016 (14/10/2016)
Latest News from
The Commission makes Erasmus+ and European Solidarity Corps more inclusive22/10/2021 15:25:00
Today, the Commission has adopted a framework to increase the inclusiveness and diversity of the Erasmus+ and European Solidarity Corps programmes for the period 2021-2027.
Remarks by President Charles Michel before the European Council meeting on 21 October 202122/10/2021 13:25:00
Remarks given yesterday by President Charles Michel before the European Council meeting.
Main messages from the Tripartite Social Summit22/10/2021 09:25:00
EU leaders and social partners met, via video conference, at the Tripartite Social Summit to discuss "transforming Europe's recovery into long-term sustainable growth supporting more and better jobs".
Speech by Vice-President Šefčovič at the Parliament on the 2022 Commission Work Programme21/10/2021 16:33:00
Speech given recently (19 October 2021) by Vice-President Šefčovič at the Parliament on the 2022 Commission Work Programme.
Conference on the Future of Europe: Plenary to discuss citizens' contributions21/10/2021 15:25:00
This weekend, the Conference Plenary will discuss reports from the European Citizens' Panels, national panels and events, the EYE and the Platform.
Cybersecurity: Council adopts conclusions on exploring the potential of a joint cyber unit21/10/2021 14:33:00
The Council recently (19 October 2021) adopted conclusions inviting the EU and member states to further develop the EU cybersecurity crisis management framework, including by exploring the potential of a joint cyber unit.
2021 Enlargement package: European Commission assesses and sets out reform priorities for the Western Balkans and Turkey21/10/2021 13:25:00
The European Commission recently (19 October 2021) adopted its 2021 Enlargement Package, providing a detailed assessment of the state of play and the progress made by the Western Balkans and Turkey on their respective paths towards the European Union, with a particular focus on implementing fundamental reforms, as well as clear guidance on the reform priorities ahead.
Commission relaunches the review of EU economic governance21/10/2021 12:38:00
The European Commission recently (19 October 2021) adopted a Communication that takes stock of the changed circumstances for economic governance in the aftermath of the COVID-19 crisis and relaunches the public debate on the review of the EU's economic governance framework.
2022 Commission Work Programme: Making Europe stronger together21/10/2021 11:33:00
The Commission recently (19 October 2021) adopted its 2022 Work Programme, setting out the next steps in its bold and transformative agenda towards a post-COVID-19 Europe that is greener, fairer, more digital and more resilient.